Pathophysiology of GvHD and Other HSCT-Related Major Complications

For over 60 years, hematopoietic stem cell transplantation has been the major curative therapy for several hematological and genetic disorders, but its efficacy is limited by the secondary disease called graft versus host disease (GvHD). Huge advances have been made in successful transplantation in order to improve patient quality of life, and yet, complete success is hard to achieve. This review assimilates recent updates on pathophysiology of GvHD, prophylaxis and treatment of GvHD-related complications, and advances in the potential treatment of GvHD.

• Publication year

  2017

• Venue

  Frontiers in Immunology

• Publication date

  2017-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2017.00079PMID 28373870PMCID 5357769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease

  2018cited by this paper
• Human Regulatory T Cells Mediate Transcriptional Modulation of Dendritic Cell Function

  2017cited by this paper
• Bronchiolitis Obliterans: Pleading for a Pragmatic Approach.

  2016cited by this paper
• Acute Graft-versus-Host Disease: Novel Biological Insights.

  2016cited by this paper
• Identification and validation of biomarkers associated with acute and chronic graft versus host disease

  2016cited by this paper
• The role of danger signals and ectonucleotidases in acute graft-versus-host disease.

  2016cited by this paper
• Role of gut flora after bone marrow transplantation

  2016cited by this paper
• NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment

  2016cited by this paper
• Gut microbiome derived metabolites modulate intestinal epithelial cell damage and mitigate Graft-versus-Host Disease

  2016cited by this paper
• How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation

  2016cited by this paper
• Aberrant B-cell homeostasis in chronic GVHD.

  2015cited by this paper
• A Global Perspective

  2015cited by this paper
• GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

  2015cited by this paper
• A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

  2015cited by this paper
• Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

  2015cited by this paper
• Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation.

  2015cited by this paper
• Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome.

  2015cited by this paper
• Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.

  2015cited by this paper
• Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

  2015cited by this paper
• How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation

  2015cited by this paper
• Identification and validation of biomarkers associated with acute and chronic graft versus host disease

  2015cited by this paper
• A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

  2015cited by this paper
• Engineering more efficient multipotent mesenchymal stromal (stem) cells for systemic delivery as cellular therapy

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Role of intestinal microbiota in transplantation outcomes.

  2015cited by this paper
• Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

  2015cited by this paper
• Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

  2015cited by this paper
• Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease.

  2014cited by this paper
• Caring for the long-term survivor after allogeneic stem cell transplantation.

  2014cited by this paper
• Current issues in chronic graft-versus-host disease.

  2014cited by this paper
• an update on

  2014cited by this paper
• Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease.

  2014cited by this paper
• Clinical impact of H-Y alloimmunity

  2014cited by this paper
• Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.

  2014cited by this paper
• Minor histocompatibility antigens: past, present, and future.

  2014cited by this paper
• Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease

  2013cited by this paper
• Advances in predicting acute GVHD

  2013cited by this paper
• Controlling the frontier: regulatory T-cells and intestinal homeostasis.

  2013cited by this paper
• Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality.

  2013cited by this paper
• Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100.

  2013cited by this paper
• Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease

  2012cited by this paper
• Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

  2012cited by this paper
• Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins.

  2012cited by this paper
• Regulatory T Cells Inhibit CD8+ T-Cell Tissue Invasion in Human Skin Graft-Versus-Host Reactions

  2012cited by this paper
• The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells

  2012cited by this paper
• Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment.

  2012cited by this paper
• Immune Reconstitution and Graft-Versus-Host Reactions in Rat Models of Allogeneic Hematopoietic Cell Transplantation

  2012cited by this paper
• Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

  2012cited by this paper
• Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning

  2012cited by this paper
• Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

  2012cited by this paper
• Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

  2012cited by this paper
• The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation.

  2011cited by this paper
• Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.

  2011cited by this paper
• The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease

  2011cited by this paper
• Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

  2011cited by this paper
• Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

  2011cited by this paper
• Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD

  2011cited by this paper
• Regulatory T cells in stem cell transplantation: strategies and first clinical experiences.

  2011cited by this paper
• Expression Profiling of Major Histocompatibility and Natural Killer Complex Genes Reveals Candidates for Controlling Risk of Graft versus Host Disease

  2011cited by this paper
• Steroid-Refractory Acute GVHD: Predictors and Outcomes

  2011cited by this paper
• Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

  2011cited by this paper
• Interleukin-2 and regulatory T cells in graft-versus-host disease.

  2011cited by this paper
• The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland.

  2011cited by this paper
• Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors.

  2010cited by this paper
• Reduced mortality after allogeneic hematopoietic-cell transplantation.

  2010cited by this paper
• A MULTICENTRE STUDY

  2010cited by this paper
• Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin

  2010cited by this paper
• Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 Years On

  2010cited by this paper
• MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings

  2010cited by this paper
• Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

  2010cited by this paper
• Mediterranean Journal of Hematology and Infectious Diseases Thrombotic Microangiopathy in Haematopoietic Cell Transplantation: Update

  2010cited by this paper
• Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.

  2010cited by this paper
• Many faces of graft‐versus‐host disease

  2010cited by this paper
• The role of B cells in the pathogenesis of graft-versus-host disease.

  2009cited by this paper
• A biomarker panel for acute graft-versus-host disease.

  2009cited by this paper
• Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming

  2009cited by this paper
• First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

  2009cited by this paper
• NOD2 regulates hematopoietic cell function during graft-versus-host disease

  2009cited by this paper
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  2009cited by this paper
• The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms.

  2009cited by this paper
• Infectious complications after allogeneic stem cell transplantation: incidence in matched‐related and matched‐unrelated transplant settings

  2009cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation.

  2009cited by this paper
• Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.

  2008cited by this paper
• Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

  2008cited by this paper
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cited by this paper
• Vascular endothelium and graft-versus-host disease.

  2008cited by this paper
• Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells.

  2008cited by this paper
• Graft-versus-host disease

  2007influential reference
• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

  2006cited by this paper
• Past, present--and future?

  2005cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Regulatory T cells and intestinal homeostasis

  2005cited by this paper
• Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

  2004cited by this paper
• Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

  2004cited by this paper
• Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

  2004cited by this paper
• NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression

  2004cited by this paper
• Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.

  2003cited by this paper

• Intravital Microscopy of Mesenteric and Brain Vessels: A Valuable Tool for Leukocyte Recruitment Evaluation.

  2026cites this paper
• Long-term neurological outcome after hematopoietic stem cell transplant in juvenile Krabbe disease

  2026cites this paper
• IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

  2026cites this paper
• Acute graft-versus-host disease

  2026cites this paper
• Infused PMN-MDSCs from G-CSF–mobilized PBSCs protect against II–IV° acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

  2026cites this paper
• Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant

  2025cites this paper
• Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review.

  2025cites this paper
• Autoimmune-Like Hepatitis Following Hepatic Graft-Versus-Host Disease in an Allogenic Hematopoietic Cell Transplant Recipient

  2025cites this paper
• Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients Using Pre‐ and Post‐Transplant Factors and Computational Intelligence

  2025cites this paper
• Gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) in pediatrics: A systematic review.

  2025cites this paper
• CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather

  2025cites this paper
• iPSC stem cell banks: is it really necessary if we already have cord blood banks?

  2025cites this paper
• Pre‐Administration of Akkermansia Muciniphila Prevents the Development of Severe Acute Graft‐Versus‐Host Disease in Systemic Organs

  2025cites this paper
• Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation

  2025cites this paper
• Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions

  2025cites this paper
• Bridging the Gap Between Bone Marrow Transplantation and CAR-T Cell Therapy in Hematological Cancers.

  2025cites this paper
• Effects of a Low Versus Moderate–High Intense Exercise Program on Innate Immune Recovery, Fitness, and Quality of Life During Pediatric Allo‐HSCT—The ANIMAL Exploratory Randomized Controlled Trial

  2025cites this paper
• Selection and Characterisation of Minor Histocompatibility Antigen‐Specific Regulatory T Cells in Fully HLA‐Matched Setting for GVHD Therapy

  2025cites this paper
• Pharmacogenetics of graft-versus-host disease: a path to personalized medicine.

  2025cites this paper
• The Differentiation and Regeneration Potential of ABCB5+ Mesenchymal Stem Cells: A Review and Clinical Perspectives

  2025cites this paper
• Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy

  2025cites this paper
• Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets

  2025cites this paper
• Mesenchymal stromal cells in management of steroid refractory acute graft vesrus host disease, systematic review and meta-analysis

  2025cites this paper
• Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease

  2025cites this paper
• Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model

  2025cites this paper
• Significance and challenges of immunopharmacogenomics

  2025cites this paper
• The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases

  2025cites this paper
• DEVELOPMENT OF ENDOTHELIOPATHY: A SHARED HALLMARK ACROSS CRITICALLY ILL PATIENT POPULATIONS.

  2025cites this paper
• Unveiling WHIM syndrome: Mavorixafor's Emerging Role in Immune Restoration and Therapy.

  2025cites this paper
• Transplantation and Monitoring of a Murine Minor Histocompatibility Antigen-Mismatched Model of Graft-Versus-Host Disease.

  2025cites this paper
• Ruxolitinib in the treatment of acute corticosteroid-refractory graft-versus-host disease: a scoping review.

  2025cites this paper
• Deep insight into cytokine storm: from pathogenesis to treatment

  2025cites this paper
• Telitacicept administration improved immunoglobulin A nephropathy after hematopoietic stem cell transplantation: a case report

  2025cites this paper
• Distress, problems and unmet rehabilitation needs after haematopoietic stem cell transplantation for haematologic malignancies: A cross-sectional study.

  2025cites this paper
• Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients

  2025cites this paper
• Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ∆CD19

  2025cites this paper
• Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)

  2025cites this paper
• Cutaneous Manifestations of Pediatric Hematological Malignancies: A Narrative Review

  2025cites this paper
• Clinicopathologic Spectrum of Dermatological Diseases in Patients with Acute Myeloid Leukemia (AML): A Retrospective Study in AML Patients with Cutaneous Manifestations

  2025cites this paper
• DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.

  2025cites this paper
• Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.

  2025cites this paper
• Palmitoylethanolamide (PEA) Induces an Increase in Spleen Regulatory T Cells, Reduces CD8 + Cells and TNF‐α Levels in Target Organs, and Protects Mice From Graft‐Versus‐Host Disease‐Related Mortality Through PPAR Activation Without Compromising the Graft‐Versus‐Tumour Response

  2025cites this paper
• Approach to diarrhea in hematopoietic stem cell transplant recipients.

  2025cites this paper
• Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies

  2025cites this paper
• Pharmacological modulation of stem cells signaling pathway for therapeutic applications

  2025cites this paper
• EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation

  2024cites this paper
• Acute kidney injury in pediatric hematopoietic stem cell transplantation patients

  2024cites this paper
• Interspecies transcriptome profiles of human T cell activation and liver inflammation in a xenogeneic graft-versus-host disease model

  2024cites this paper
• Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases

  2024cites this paper
• Fecal Calprotectin: A Predictive Biomarker for Gastrointestinal Graft-versus-Host-Disease and a Prognostic Indicator in their Steroid therapy

  2024cites this paper
• Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant

  2024cites this paper
• Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes

  2024cites this paper
• Initiation of Haploidentical Stem Cell Transplantation With Post‐Transplant Cyclophosphamide in Children: A Low–Middle‐Income Country Institutional Experience

  2024cites this paper
• Severe corneal manifestations of graft-versus-host disease: experience of a tertiary referral center.

  2024cites this paper
• A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease

  2024cites this paper
• Harnessing Immunomodulatory Polymers for Treatment of Autoimmunity, Allergy, and Transplant Rejection.

  2024cites this paper
• The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice

  2024cites this paper
• Transplantation of Donor–Recipient Chimeric Cells Restores Peripheral Blood Cell Populations and Increases Survival after Total Body Irradiation-Induced Injury in a Rat Experimental Model

  2024cites this paper
• Application of CD25 and CTLA4 gene transcription levels in early prediction of acute graft-versus-host disease

  2024cites this paper
• Alteration of Gut Microbiota Composition and Diversity in Acute and/or Chronic Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study

  2024cites this paper
• Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation

  2024cites this paper
• Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?

  2024cites this paper
• Diagnostic prediction of gastrointestinal graft-versus-host disease based on a clinical- CT- signs nomogram model

  2024cites this paper
• Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association.

  2024cites this paper
• The Role of Extracorporeal Photopheresis in the Management of Graft Versus Host Disease: Narrative Review.

  2024cites this paper
• Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS in vitro and correlates with inflammatory parameters and clinical severity

  2024cites this paper
• How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

  2024influential citation
• [Cell therapy in all its forms].

  2024cites this paper
• Alantolactone ameliorates graft versus host disease in mice.

  2024cites this paper
• Biological markers of bronchiolitis obliterans syndrome in recipients of allogeneic hematopoietic stem cell transplantation

  2024cites this paper
• Withania Somnifera Extract Mitigates Experimental Acute Graft versus Host Disease Without Abrogating Graft Versus Leukemia Effect

  2024cites this paper
• Plasma Cell-Free RNA Captures Immune Dynamics and Predicts GVHD after Hematopoietic Stem Cell Transplantation

  2024cites this paper
• Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  2024cites this paper
• An Ethical Framework for Allergy and Immunology.

  2024cites this paper
• Special Section on Clinical Pharmacology Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers S

  2023cites this paper
• Novel therapies for graft versus host disease with a focus on cell therapies

  2023cites this paper
• Graft-versus-host disease following liver transplantation: A systematic review of literature

  2023cites this paper
• Temporal regulation of transgene expression controlled by amino acid availability in human T cells

  2023cites this paper
• Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

  2023cites this paper
• Hematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview

  2023cites this paper
• Acute graft versus host disease after liver transplantation: where do we stand?

  2023cites this paper
• Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications

  2023cites this paper
• Impact of oral microbiota on pathophysiology of GVHD

  2023cites this paper
• Pathophysiology of gastrointestinal acute graft‐versus‐host disease and the potential role of glucagon‐like peptide 2

  2023influential citation
• Cardiovascular Events After Hematopoietic Stem Cell Transplant

  2023cites this paper
• Graft versus Leukemia in 2023.

  2023cites this paper
• Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation

  2023cites this paper
• Diagnostic yield for video capsule endoscopy in gastrointestinal graft- versus -host disease: a systematic review and metaanalysis

  2023cites this paper
• Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT

  2023cites this paper
• Immunological aspects of hematopoietic stem cell transplantation for hematologic malignancies and some immunological peculiarities of cancer radioimmunotherapy

  2023cites this paper
• The impact of NKG2A and NKG2D receptors and HLA-E and MICA ligands polymorphisms on post-transplant complications after paediatric allogeneic HSCT: a single-centre experience

  2023cites this paper
• Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers

  2023cites this paper
• Role of Defibrotide in the prevention of murine model graft versus host disease after allogeneic hematopoietic cell transplantation.

  2023cites this paper
• Distributions of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 alleles and haplotype frequencies of 1763 stem cell donors in the Colombian Bone Marrow Registry typed by next-generation sequencing

  2023cites this paper
• Ocular graft-versus-host disease (oGVHD): From A to Z.

  2023cites this paper
• Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

  2023cites this paper
• Regulation of hematopoietic stem cells differentiation, self-renewal, and quiescence through the mTOR signaling pathway

  2023cites this paper
• Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases

  2023cites this paper
• Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) - Case series.

  2023cites this paper
• Role of Gut Microbiota and Oxidative Stress in the Progression of Transplant-Related Complications following Hematopoietic Stem Cell Transplantation

  2023cites this paper